Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROfound: Olaparib in mCRPC
NCT02987543Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of olaparib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Radiological Progression Free Survival up to 7 months. Started Feb 2017; status: completed.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02987543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987543.